对体能状态较差的晚期胃癌患者应用奥沙利铂、亚叶酸钙和5-氟尿嘧啶方案的回顾性研究：印度南部一家三级中心的研究
Retrospective study of oxaliplatin, leucovarin and 5 fluoruracil regimen in patients with advanced gastric cancer with poor performance status: A study at a tertiary center of South India.
作者信息
Bhat Guruprasad
机构信息
Department of Medical Oncology, Yenepoya Medical College, Mangalore, Karnataka, India.
出版信息
South Asian J Cancer. 2018 Oct-Dec;7(4):223-225. doi: 10.4103/sajc.sajc_1_18.
BACKGROUND
Gastric carcinoma is the leading cause of cancer in south India. Gastric cancer is frequently diagnosed in locally advanced or metastatic setting in Indian scenario and has a poor survival. There is no standard chemotherapy regimen which can be used in advanced gastric cancer (AGC) patients.
OBJECTIVE
The aim of this study was to assess the clinical activity and toxicity of oxaliplatin with infusional 5-fluorouracil and leucovorin administered every 3 weeks in patients with locally advanced and inoperable gastric cancer.
PATIENTS AND METHODS
In this retrospective study, the case records of 25 patients who have received OLF regimen were analyzed.
RESULTS
The median number of cycles for patients was 6 (range: 4-12 cycles). Overall response rate was 36%, with all patients having stable disease. Median survival of patients was 6 months (7 months in locally advanced). Compared to other regimens, there was less toxicity (less hematologic toxicity, less nausea and vomiting, no hair loss, no renal toxicity, no hand foot syndrome, and lesser admissions).
CONCLUSIONS
OLF regimen is an acceptable regimen in poor performance status AGC patients with adequate response and an acceptable toxicity profile.
背景
胃癌是印度南部癌症的主要病因。在印度，胃癌常被诊断为局部晚期或转移性疾病，生存率较低。目前尚无可用于晚期胃癌（AGC）患者的标准化疗方案。
目的
本研究旨在评估每3周给予奥沙利铂联合持续静脉输注5-氟尿嘧啶和亚叶酸钙治疗局部晚期不可切除胃癌患者的临床活性和毒性。
患者与方法
在这项回顾性研究中，分析了25例接受OLF方案治疗患者的病例记录。
结果
患者的中位周期数为6个周期（范围：4 - 12个周期）。总缓解率为36%，所有患者病情稳定。患者的中位生存期为6个月（局部晚期患者为7个月）。与其他方案相比，该方案毒性较小（血液学毒性较小、恶心呕吐较少、无脱发、无肾毒性、无手足综合征且住院次数较少）。
结论
OLF方案对于身体状况较差的AGC患者是一种可接受的方案，疗效适当且毒性可接受。
Zotero 插件